Zensun (Shanghai) Science & Technology, Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
9
Ending by 2030
Dec 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 28, 2027The maintenance fee for Neuregulin based methods for treating heart failure (US 9,089,524) comes due Jan 28, 2027. Unpaid by Jul 28, 2027, it lapses early.
- 1 fee due Mar 19, 2027The maintenance fee for Composite vitamin composition promoting gastrointestinal system motility (US 11,759,463) comes due Mar 19, 2027. Unpaid by Sep 20, 2027, it lapses early.
- 1 fee due Apr 15, 2027The maintenance fee for Uses of neuregulin in preventing, treating or delaying ventricular arrhythmia, and composition thereof (US 10,441,633) comes due Apr 15, 2027. Unpaid by Oct 15, 2027, it lapses early.
- 1 fee due May 28, 2027The maintenance fee for Neuregulin based compositions and uses thereof for preventing, treating or delaying the myocardial ischemia-reperfusion injury (US 11,826,400) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
- 1 fee due Aug 18, 2027The maintenance fee for Methods and compositions of neuregulins for preventing, treating or delaying preserved ejection fraction cardiac failure (US 10,561,709) comes due Aug 18, 2027. Unpaid by Feb 18, 2028, it lapses early.
- 1 fee due Oct 30, 2027The maintenance fee for Formula of neuregulin preparation (US 11,969,458) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,638,746 | Extended release of neuregulin for improved cardiac function In force · USPTO record | In force | USPTO record | |
| US 10,227,418 | Neukinase, a Downstream Protein of Neuregulin In force · Medium confidence | In force | Medium confidence | |
| US 9,580,515 | Neukinase, a downstream protein of neuregulin In force · USPTO record | In force | USPTO record | |
| US 9,012,400 | Neuregulin peptides and their use In force · USPTO record | In force | USPTO record | |
| US 9,434,777 | Neuregulin peptides and their use In force · USPTO record | In force | USPTO record | |
| US 8,609,620 | Neuregulin peptides and their use In force · USPTO record | In force | USPTO record | |
| US 11,246,909 | Neuregulin based methods for treating heart failure In force · USPTO record | In force | USPTO record | |
| US 9,655,949 | Neuregulin based methods for treating heart failure In force · USPTO record | In force | USPTO record | |
| US 12,133,882 | Neuregulin Based Methods for Treating Heart Failure In force · Low confidence | In force | Low confidence | |
| US 11,826,400 | Neuregulin based compositions and uses thereof for preventing, treating or delaying the myocardial ischemia-reperfusion injury In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 32: 2 lapsed for an unpaid fee · 10 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 3 abandoned · 19 no status recorded